CDK
Cyclin dependent kinase
CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.
There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.
CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).
Alle CDK Isoform-spezifische Produkte anzeigen
-
CDK
(486)
View all products
-
CDK1
(198)
View all products
-
CDK2
(316)
View all products
-
CDK3
(28)
View all products
-
CDK4
(236)
View all products
-
CDK5
(98)
View all products
-
CDK6
(179)
View all products
-
CDK7
(119)
View all products
-
CDK8
(57)
View all products
-
CDK9
(206)
View all products
-
CDK11
(9)
View all products
-
CDK12
(54)
View all products
-
CDK13
(28)
View all products
-
CDK14
(6)
View all products
-
CDK16
(8)
View all products
-
CDK19
(25)
View all products
-
CDC
(21)
View all products
-
CLK
(31)
View all products
-
Pho85
(1)
View all products
-
CDK10
(1)
View all products
-
CDK15
(1)
View all products
-
CDK17
(2)
View all products
-
CDK18
(1)
View all products
-
CDK20
(1)
View all products
-
PITSLRE
(1)
View all products
All Product Categories
-
CDK Inhibitors
(1088)
View all products
-
CDK Agonists
(3)
View all products
-
CDK Antagonists
(2)
View all products
-
CDK Activators
(18)
View all products
-
CDK Modulators
(15)
View all products
-
CDK Degraders
(95)
View all products
-
CDK Controls
(4)
View all products
-
CDK Substrate
(1)
View all products
-
CDK Ligands
(16)
View all products
-
Cyclin-Dependent Kinases (CDKs) Proteins
(80)
View all products
-
Cyclin Dependent Kinase 1 (CDK1) Proteins
(9)
View all products
-
Cyclin-Dependent Kinase 2 (CDK2) Proteins
(12)
View all products
-
Cyclin-Dependent Kinase 3 (CDK3) Proteins
(6)
View all products
-
Cyclin-Dependent Kinase 4 (CDK4) Proteins
(4)
View all products
-
Cyclin-Dependent Kinase 5 (CDK5) Proteins
(5)
View all products
-
Cyclin-Dependent Kinase 6 (CDK6) Proteins
(6)
View all products
-
Cyclin-Dependent Kinase 7 (CDK7) Proteins
(4)
View all products
-
CDK Verwandte Produkte (1364)
Verwandte Produkte (1364)
-
Recombinant Proteins (82)
-
Antibodies (42)
-
CDK Isoform Comparison
-
Cdk2 Rat Pre-designed siRNA Set A
0 ImagesArt. -Nr.: HY-RS02376 -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
CDK2-IN-29
0 ImagesArt. -Nr.: HY-160941CAS. Nr.: 247149-58-2CDK2-IN-29 (Compound 13q) is an inhibitor for cyclin-dependent kinase (CDK), with IC50 of 96 nM and 360 nM, for CDK 2 and CDK 4, respectively. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
IRAK4-IN-35
0 ImagesArt. -Nr.: HY-187692CAS. Nr.: 3112339-39-3IRAK4-IN-35 is an orally active IRAK4 inhibitor with an IRAK4 IC50 of 9.88 nM. IRAK4-IN-35 also inhibits JAK3, EGFR, CDK2 with IC50 values of 6.72 nM, 32.35 nM, and 39.08 nM, respectively. IRAK4-IN-35 inhibits the production of proinflammatory cytokines, blocks inflammatory signaling pathways, and reduces serum TNF-α levels and spleen index in mouse models of acute inflammation. IRAK4-IN-35 decreases the disease activity index, paw swelling degree, and spleen index in a collagen-induced arthritis mouse model. IRAK4-IN-35 can be used for the research of rheumatoid arthritis. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
CDK8-IN-19
0 ImagesArt. -Nr.: HY-176282CDK8-IN-19 (Compound 3d) is a CDK8 inhibitor with an IC50 of 25.08 nM. CDK8-IN-19 has a broad-spectrum anticancer activity, such as leukemia, melanoma and breast cancer, without significant cytotoxic effect on the normal Vero cells (mean IC50s of 2.87, 3.65, 3.79 and 45.48 μM, respectively). -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Autophagy agonist-1
0 ImagesArt. -Nr.: HY-170992Autophagy agonist-1 (compound 22) is an Autophagy agonist. Autophagy agonist-1 exhibits significant anticancer activity against HepG2 cells and normal cells with IC50s of 8.8 μM and > 50 μM. Autophagy agonist-1 induces G1/S phase cell cycle arrest and inhibits CDK4 and CyclinD1 expression while upregulating P21. Autophagy agonist-1 promotes the accumulation of autophagosomes and the proteins LC3 and PINK1, enhancing autophagy and mitophagy in HepG2 cells. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
3-Methylthienyl-carbonyl-JNJ-7706621
0 ImagesArt. -Nr.: HY-141685CAS. Nr.: 443798-09-23-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of cyclin-dependent kinase (CDK), with IC50s of 6.4 nM and 2 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. 3-Methylthienyl-carbonyl-JNJ-7706621 also shows potent inhibition of GSK-3 (IC50=0.041 μM) and modest potency against CDK4, VEGF-R2, and FGF-R2 (IC50=0.11, 0.13, 0.22 μM, respectively). 3-Methylthienyl-carbonyl-JNJ-7706621 can be used for the research of cancer. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
EGFR/HER2/CDK9-IN-3
0 ImagesArt. -Nr.: HY-147798CAS. Nr.: 422276-47-9 -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
- YL-1-9
-
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
CDK7-IN-8
0 ImagesArt. -Nr.: HY-143586CAS. Nr.: 2654003-64-0 -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
CDK11-IN-1
0 ImagesArt. -Nr.: HY-182764CDK11-IN-1 is an orally active cyclin-dependent kinase 11 (CDK11) inhibitor with an IC50 of 4 nM, and it exhibits high selectivity against other kinases including CDK7 and CDK9. CDK11-IN-1 inhibits tumor growth in lung cancer xenograft models. CDK11-IN-1 can be used for lung cancer research. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
EGFR/HER2/CDK9-IN-1
0 ImagesArt. -Nr.: HY-147796CAS. Nr.: 879730-44-6 -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
SC-60
0 ImagesArt. -Nr.: HY-W717425CAS. Nr.: 1421677-31-7SC-60 is a derivative of Sorafenib (HY-10201). SC-60 exerts its anti-tumor effect by activating the phosphatase activity of SHP-1, thereby inhibiting the STAT3 signaling pathway. SC-60 exhibits strong proliferation inhibitory activity in various hepatocellular carcinoma (HCC) cell lines. SC-60 downregulates the expression of downstream anti-apoptotic proteins (such as Bcl-2, Cyclin D1, Survivin), ultimately inducing caspase-dependent apoptosis. SC-60 significantly inhibits tumor growth in xenograft tumor models. SC-60 can be used for the study of HCC. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
CDK4-IN-6
0 ImagesArt. -Nr.: HY-184418CAS. Nr.: 3120500-44-6 -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
STAT3-IN-32
0 ImagesArt. -Nr.: HY-164445CAS. Nr.: 2591440-71-8STAT3-IN-32 is an orally active, selective STAT3 SH2 domain inhibitor with a Kd of 21.3 nM, showing selectivity over STAT1/5. STAT3-IN-32 binds to the STAT3 SH2 domain, blocks Tyr705 and Ser727 phosphorylation, abrogates nuclear transcription and mitochondrial oxidative phosphorylation functions. STAT3-IN-32 inhibits tumor growth in mouse pancreatic cancer xenograft models. STAT3-IN-32 can be used for the research of pancreatic cancer. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
MFDCH016
0 ImagesArt. -Nr.: HY-178350MFDCH016 is a potent HDAC1/6 (IC50 = 38/59 nM) and CDK4/6 (IC50 = 680/720 nM) inhibitor. MFDCH016 induces apoptosis and cell cycle arrest in G2/M and G0/G1 phases in MCF-7 cells. MFDCH016 can modulate the HDAC-p21-CDK signaling pathway, increasing the levels of acetylated H3 and p21. MFDCH016 can be used for the study of breast cancer. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Cdc7-IN-19
0 ImagesArt. -Nr.: HY-143433CAS. Nr.: 2606780-39-4Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC50 of 1.49 nM. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
SY-5102
0 ImagesArt. -Nr.: HY-180355CAS. Nr.: 2365230-48-2SY-5102 is a potent, selective, and orally active cyclin-dependent kinase (CDK7) inhibitor with a Kd value of 0.03 nM. SY-5102 occupies the ATP-binding pocket of CDK7 via non-covalent binding to inhibit CDK7 activity, and downregulates its phosphorylation of cyclin CDK and RNA polymerase II. SY-5102 inhibits cancer cell proliferation, and induces tumor growth inhibition and regression. SY-5102 can be used in research related to triple-negative breast cancer. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
SB-1295
0 ImagesArt. -Nr.: HY-155065SB-1295 is an orally active CDK9/T1 inhibitor (IC50=0.17 μM). SB-1295 shows antiproliferative activity in HCT 116 and MIA PaCa-2 cells. SB-1295 also induces MIA PaCa-2 cell death by inducing intracellular ROS production, reducing mitochondrial membrane potential and inducing apoptosis. SB-1295 has the potential to study cancer. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
- Protein kinase inhibitor 11
-
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
EGFR-IN-182
0 ImagesArt. -Nr.: HY-178955EGFR-IN-182 (Compound 4) is an EGFR inhibitor with an IC50 value of 199 nM. EGFR-IN-182 inhibits HSP90 and PI3K, with IC50 values of 5.007 and 13.596 μM respectively. EGFR-IN-182 exhibits strong anti-proliferative activity against MCF-7 and MDA-MB-231 cells. EGFR-IN-182 downregulates Cyclin D1, inducing cell cycle arrest; it enhances the activity of caspase-9, inducing cell apoptosis. EGFR-IN-182 downregulates the expressions of ERK and AKT. EGFR-IN-182 can be used for research on breast cancer. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
No matching results
No matching results
No matching results
No matching results
-
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
Your Search Returned No Results.
Sorry. There is currently no product that acts on isoform Bcl-2, Bcl-W and Bim together.Please
try each isoform separately.